Skip to main content
Premium Trial:

Request an Annual Quote

GenomeWebinars: Recent

Oct
18
2021

Sponsored by Thermo Fisher Scientific

Institutional Lessons From Implementing Plasma Genotyping to Monitor Response and Treatment in Non-Small Cell Lung Cancer

Nearly 70 years after the discovery of cell-free DNA, plasma genotyping is routinely used to non-invasively detect and quantify clinically relevant point mutations, insertions/deletions, amplifications, rearrangements, and aneuploidy. Over the past eight-plus years, strong concordance has been shown between plasma and tissue-based genomic assays, encouraging the clinical adaptation of plasma genotyping. In this webinar, Dr. Cloud Paweletz will present institutional experiences implementing liquid biopsies into non-small cell lung cancer. He will discuss technical limitations and lessons learned with a particular focus on minimal residual disease, treatment response, and the emergence of resistance monitoring. The realization of these lessons, however, spurs significant investment in techniques and technologies to increase specificity and sensitivity and reduce turnaround time and cost for further clinical adoption of this promising diagnostic.

Sponsored by

Oct
15
2021

Sponsored by Cepheid

Antimicrobial Resistance in the Wake of COVID-19: How Healthcare Systems Can Use Molecular Testing to Stem the Tide

As the COVID-19 pandemic rages on, data have shown that other aspects of healthcare are being neglected by patients and physicians alike, including practicing good stewardship to battle antibiotic-resistant bacteria. Earlier this year, the US Centers for Disease Control noted that COVID-19 can create a "perfect storm" for antibiotic-resistant infections in healthcare settings due to longer hospital stays, staffing shortages, a higher number of sick patients, and difficulties implementing infection control practices. The CDC also noted that the number of bacterial and fungal specimens and isolates received and/or tested in 2020 by CDC's antibiotic resistance lab network was about 23 percent less than 2019 levels.

More recently, in September, a CDC study published in Infection Control and Hospital Epidemiology revealed initial increases early in 2020 for ventilator-associated events (VAEs), central line-associated bloodstream infections (CLABSIs), and methicillin-resistant Staphylococcus aureus (MRSA) bacteremia. In addition, compared to 2019, the second half of 2020 saw large and significant increases in catheter-associated urinary tract infections, VAEs, CLABSIs, and MRSA bacteremia.

Although it is still unclear whether this is a burgeoning trend or a blip on the radar, molecular testing remains one of the most important public health tools available for keeping antibiotic resistance in check. In this roundtable discussion, researchers and lab directors from four highly renowned US academic institutions and healthcare organizations will share their thoughts on what they're seeing on the antimicrobial stewardship front; the role of molecular testing in combatting AMR; what challenges they are seeing in their organizations; and what tools and technologies are available or on the horizon to help with the fight.

The session will include a live Q&A in which attendees can post questions to our panelists: Kevin Alby, Ph.D., D(ABMM) (Assistant Professor, Pathology and Laboratory Medicine Director, Bacteriology and Susceptibility Testing, Associate Director, Clinical Microbiology Laboratory, UNC School of Medicine, Chapel Hill, NC); Romney M. Humphries, Ph.D., D(ABMM), M(ASCP) (Professor of Pathology, Microbiology, and Immunology Medical Director of the Microbiology Laboratory); Dr. Patricia Simner, PhD, D(ABMM) (Associate Professor of Pathology at the Johns Hopkins University School of Medicine, Director of the Medical Bacteriology and Infectious Disease Sequencing Laboratories at the Johns Hopkins Hospital); Glen Hansen, PhD (Hennepen Healthcare).

Sponsored by

Oct
05
2021

Sponsored by Qlucore

Using RNA-seq for the Diagnosis of Acute Lymphoblastic Leukemia

In this brief video from Qlucore, Thoas Fioretos, professor in clinical genetics at Lund University in Sweden, discusses the benefits of using RNA-seq to diagnose acute lymphoblastic leukemias (ALLs), the great majority of which are characterized by gene fusions or display a distinct gene expression signature that can be used for classification.

Sponsored by

Oct
05
2021

Sponsored by Qlucore

Benefits of Using RNA-seq for Clinical Cancer Diagnostics

In this brief video from Qlucore, Thoas Fioretos, professor in clinical genetics at Lund University in Sweden, discusses the major benefits of using RNA-seq in the clinical setting, including patient subtyping and risk stratification, gene expression subtype classification models, and gene fusion analysis.

Sponsored by

Oct
05
2021

Sponsored by Qlucore

Using NGS and RNA-seq in Clinical Cancer Diagnostics

In this webinar from Qlucore, Thoas Fioretos, professor in clinical genetics at Lund University in Sweden, answers questions about using RNA-seq in clinical diagnostics, meeting future needs in precision diagnostics, and new in vitro diagnostics regulations. Dr. Fioretos discusses the benefits of using next-generation sequencing, the added value of using whole transcriptome RNA sequencing — such as with novel and known gene fusions and gene expression-based classification — and the trends and future needs in clinical diagnostics.

Sponsored by

Sep
29
2021

Sponsored by Millipore Sigma

Development of New Metabolism-Based Multi-Cancer Biomarkers to Detect the Earliest Stages of Cancer

This webinar will address the need for innovation in the early detection of cancer and the approach taken by Elypta, a Swedish cancer detection firm, to develop new metabolism-based biomarkers.

Elypta was funded by the EU Horizon 2020 program to bring the first kidney cancer recurrence test to market. Elypta’s approach is based on profiling glycosaminoglycans — or the GAGome — and developing scores indicative of cancer. At the 2021 American Society of Clinical Oncology conference, a proof-of-concept study across 14 cancer types revealed the broader potential for early detection using the technology, highlighting the sensitivity to stage I disease.

Karl Bergman, CEO of Elypta, will discuss the need for new cancer biomarkers and Elypta’s results highlighting the potential of glycosaminoglycans as a tool in early detection. He will also outline the path Elypta took to develop their research-use-only (RUO) kits, partnering with MilliporeSigma at an early stage to ensure a clear path to large-scale in vitro diagnostic (IVD) manufacturing and enabling the Elypta team to focus their efforts on research and development.

Michael Mitchell, commercial project manager at MilliporeSigma, will discuss the milestones and challenges of MilliporeSigma’s work with Elypta. Mitchell will cover highlights from the set-up, pilot, and engineering phases of Elypta’s RUO cancer detection kit, as well as the preparative work for their IVD offering.

Attendees will learn:

  • Why more biomarkers are needed for the earliest stages of cancer
  • Key aspects and results from the GAGome-based liquid biopsy platform developed by Elypta
  • How a partnership with MilliporeSigma helped Elypta in the development journey

Sponsored by

field_file_image_alt_text_value
Sep
22
2021

Sponsored by PerkinElmer

Roundtable: Challenges and Opportunities for At-Home Infectious Disease Testing

The potential for tests that can be done at home from start to finish to tell people whether they are healthy enough to interact with others has never been so important. But what have we learned during the pandemic about the feasibility of testing at home? Is a permanent shift toward rapid, more convenient testing at home more likely given the recent higher profile of rapid tests?

Our expert panelists will discuss these trends and address which diagnostic market segments may be most amenable to adoption, which challenges need to be addressed before such testing at a broader scale can materialize, and what the implications are for laboratories of a potential shift in testing toward the home.

Sponsored by

field_file_image_alt_text_value
Sep
08
2021

Sponsored by LumiraDx

Application of a Mobile Unit for High-Throughput Molecular Testing for COVID-19

SafeTogether mobile units can perform accurate and immediate COVID-19 testing with sophisticated laboratory equipment that is usually only found in central or reference laboratories to help accurate and immediate COVID-19 testing. As we look beyond the pandemic, the units can be shared across cities or counties where healthcare is needed most.

In this webinar, Dr. Phil Radford, CEO and founder of Radeas, will discuss the development of the mobile lab units through a collaboration between the engineering and construction company Black & Veatch, the high complexity clinical lab Radeas/Circumference, and the LumiraDx FastLab team with their RNA STAR Complete SARS-CoV-2 Assay. The assay utilizes a direct amplification method to detect SARS-CoV-2 viral nucleic acid in under 20 minutes on common open channel PCR systems — a process which typically takes more than one hour — making it an ideal system to serve mass testing applications.

Sponsored by

Jul
26
2021

Sponsored by Inivata

Utility of ctDNA-Based Liquid Biopsy Testing in the Detection of Molecular Residual Disease and Recurrence in Patients with Early-Stage Non-Small Cell Lung Cancer

In the era of precision oncology, the use of liquid biopsy testing in patients with non-small cell lung cancer (NSCLC) and other solid cancers is rapidly evolving. Recent evidence has shown an increasing capability to detect circulating tumor DNA (ctDNA) in patients with localized, early-stage NSCLC with potential applications to personalize treatment decisions. However, detection of ctDNA continues to prove challenging. This webinar will discuss expert insights and summarize recent findings on how ctDNA testing can be applied to detect molecular residual disease (MRD) and early risk of relapse ahead of standard-of-care imaging surveillance. Are we ready to explore the potential applications of ctDNA-guided adjuvant trials in NSCLC?

In this webinar you will learn:

  • A clinician’s perspective and outlook on unmet medical need in early-stage NSCLC treatment paradigms, focusing on adjuvant and surveillance settings
  • Current clinical evidence for the use of MRD assessment in NSCLC clinical studies, how we can encourage uptake by clinicians/biopharma, and what needs to be done to enable clinical routine implementation
  •  Evidence of ctDNA detection in early-stage NSCLC: results from the LUng cancer Circulating tumor DNA (LUCID) study
  •  The current technology, emerging applications, and challenges of ctDNA
  •  The key considerations of liquid biopsy-based MRD testing

Sponsored by

Jul
21
2021

Sponsored by Qiagen

The Importance of FGFR as a Biomarker in Bladder Cancer

Certain FGFR alterations are key drivers of tumor growth in urothelial cancer, which is the sixth most common type of cancer in the US and is associated with poor prognosis. Erdafitinib has been approved for the treatment of urothelial carcinoma patients whose tumors harbor specific FGFR mutations or fusions. QIAGEN’s therascreen FGFR RGQ RT-PCR Kit was developed and FDA-approved as a companion diagnostic to identify such FGFR alterations.

In this discussion, expert panelists will examine the biological relevance and clinical significance of FGFR alterations and how FGFR testing can be leveraged to identify eligible patients.

The therascreen FGFR RGQ RT-PCR Kit is intended for in vitro diagnostic use. Product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.

Sponsored by

field_file_image_alt_text_value
Jul
21
2021

Sponsored by Qiagen

The Importance of FGFR as a Biomarker in Bladder Cancer

Certain FGFR alterations are key drivers of tumor growth in urothelial cancer, which is the sixth most common type of cancer in the US and is associated with poor prognosis. Erdafitinib has been approved for the treatment of urothelial carcinoma patients whose tumors harbor specific FGFR mutations or fusions. QIAGEN’s therascreen FGFR RGQ RT-PCR Kit was developed and FDA-approved as a companion diagnostic to identify such FGFR alterations.

In this discussion, expert panelists will examine the biological relevance and clinical significance of FGFR alterations and how FGFR testing can be leveraged to identify eligible patients.

The therascreen FGFR RGQ RT-PCR Kit is intended for in vitro diagnostic use. Product claims may differ from country to country based on regulations and approvals. Contact your country representative for further details.

Sponsored by

field_file_image_alt_text_value
Jul
14
2021

Sponsored by LGC SeraCare Life Sciences

Genomic Testing to Support New Therapies for Advanced Cancer Patient Care: A Panel Discussion

Molecular profiling of tumors has expanded the treatment options for patients with a wide variety of high prevalence cancers and cancers associated with high death rates, such as lung, colon, prostate, and breast. Overall, combining genetic testing with targeted therapies is extending survival while minimizing adverse effects. This webinar will bring together leading experts in molecular pathology, NGS tumor profiling, companion diagnostics development, and precision oncology for a panel discussion. The panelists will discuss topics including today’s achievements advancing precision diagnostics and how to address the many unmet laboratory and testing needs required to support continuous improvement of cancer patient therapy.  

The panelists on this webinar are Dara L. Aisner, MD PhD, Associate Professor, Director Colorado Molecular Correlates Laboratory, Department of Pathology at the University of Colorado, George Green, PhD, Executive Director, Head Pharmacodiagnostics at Bristol-Myers Squibb, Greg Tsongalis, PhD, Director of the Laboratory for Clinical Genomics and Advanced Technologies at Theodor Geisel School of Medicine at Dartmouth and Russell Garlick, PhD, Chief Scientific Officer at LGC Clinical Diagnostics.

Sponsored by

field_file_image_alt_text_value
Jun
24
2021

Sponsored by Thermo Fisher Scientific

The Future of Point-of-Care Testing: How Can Test Developers Meet Rising Demand for Evolving End Markets?

Point-of-care tests have been available to clinicians and consumers for decades, but more recently, molecular testing technologies that can be used at the point of care are making inroads.

For now, these molecular point-of-care tests are used largely for infectious disease testing, especially for the flu, and, more recently, COVID-19. But new technology developments are driving applications in new disease areas and end markets, including physician offices, emergency rooms, and CLIA-waived settings.

However, broad adoption of such technologies is not guaranteed. Along with ensuring high accuracy and ease of use, test developers must navigate pricing considerations, regulatory issues, and competition, not only from other molecular point-of-care tests, but also from more traditional tests.

In this roundtable discussion, industry stakeholders, including test developers and a venture capital fund, will discuss new molecular point-of-care testing technologies on the horizon, the technical challenges of developing such tests, and other challenges and opportunities ahead. 

The session will include a live Q&A in which attendees can post questions to our panelists.

Our panelists on this session are Jonathan O'Halloran, CEO at QuantuMDx; Brian Coe, CEO at Talis Biomedical; Justin Kao, partner at Khosla Ventures; and Dr. Tim Sweeney, CEO at Inflammatix.

Sponsored by

Jun
23
2021

Sponsored by Ionpath

Predicting Cancer Progression – Development of Spatial Proteomic Signatures

Ductal carcinoma in situ (DCIS) is a pre-invasive lesion that is thought to be a precursor to invasive breast cancer (IBC). DCIS comprises approximately 20% of newly diagnosed breast cancer cases, and unlike IBC is not life-threatening. However, if left untreated, up to half of DCIS patients will develop IBC within 10 years, so clinical management has trended towards presuming all patients are progressors and treating them with surgery, radiation therapy, and pharmacological interventions. Thus, understanding the central biological features in DCIS that drive the transition to IBC is a critical unmet need for guiding appropriate patient care.

In this webinar, Dr. Michael Angelo will discuss research his lab conducted to understand how the tumor microenvironment (TME) changes with transition to IBC. Angelo and colleagues used Multiplexed Ion Beam Imaging (MIBI) and a 37-plex antibody staining panel to analyze over 100 clinically annotated surgical resections covering the full spectrum of breast cancer progression. The team compared normal, DCIS, and IBC tissues using machine learning tools for multiplexed cell segmentation, pixel-based clustering, and object morphometrics. They found the transition from DCIS to IBC to progress by coordinated shifts in location and function of myoepithelium, fibroblasts, and infiltrating immune cells in the surrounding stroma. This study offers insight into the etiologies of DCIS and its transition to IBC—emphasizing the importance of the TME stroma—and may serve as a template for how to carry out similar analyses of preinvasive cancers using MIBI spatial proteomic signatures.

Sponsored by

Jun
23
2021

Sponsored by Invitae

Expanded Biomarker Research in Non-Small Cell Lung Cancer Using RNA Next-Generation Sequencing

The discovery of targetable oncogenic biomarkers in non-small cell lung cancer (NSCLC) has revolutionized its treatment. Current guidelines recommend fast and comprehensive biomarker screening for the selection of first-line targeted therapy or immunotherapy with or without chemotherapy. The number of actionable targets and the requirement for extensive molecular screening strategies are expected to increase in the coming years. This webinar will summarize how NSCLC biomarker testing can be expanded by RNA next-generation sequencing. In this webinar you will learn:

  • The nature of clinical NSCLC biomarker testing in Europe
  • A clinician’s perspective on why the clinical environment should drive the focus of research testing
  • How Invitae’s expanded lung in-house panel* is well positioned to drive successful research testing

*Current products are for research use only, not for use in diagnostic procedures.

Sponsored by